Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014

Journal of Clinical Oncology

Volumn 34, Issue 24, 2016, Pages 2858-2865

  Solomon, Benjamin J ^a   Cappuzzo, Federico ^b   Felip, Enriqueta ^d   Blackhall, Fiona H ^e   Costa, Daniel B ^f   Kim, Dong Wan ^h   Nakagawa, Kazuhiko ⁱ   Wu, Yi Long ^j   Mekhail, Tarek ^g   Paolini, Jolanda ^c   Tursi, Jennifer ^c   Usari, Tiziana ^c   Wilner, Keith D ^c   Selaru, Paulina ^c   Mok, Tony S K ^k  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c PFIZER INC   (United States)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g FLORIDA HOSPITAL   (United States)

^h Seoul National University Hospital   (South Korea)

ⁱ KINKI UNIVERSITY   (Japan)

^j GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BRADYCARDIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DRUG ADMINISTRATION; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SECONDARY; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEMETREXED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84979027920     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.5888     Document Type: Article

References (27)

1. Christensen JG, Zou HY, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314-3322, 2007
2. Yasuda H, De Figueiredo-Pontes LL, Kobayashi S, et al: Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7:1086-1090, 2012
3. National Comprehensive Cancer Network: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-small cell lung cancer version 4. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
4. Solomon BJ, Mok T, Kim DW, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
5. Nguyen KS, Neal JW, Wakelee H: Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 5:576-587, 2014
6. Rolfo C, Passiglia F, Ostrowski M, et al: Improvement in lung cancer outcomes with targeted therapies: An update for family physicians. J Am Board Fam Med 28:124-133, 2015
7. Kelly K, Bunn PA Jr: Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 20:85-91, 1998
8. Guérin A, Sasane M, Zhang J, et al: Brain metastases in patients with ALK+ non-small cell lung cancer: Clinical symptoms, treatment patterns and economic burden. J Med Econ 18:312-322, 2015
9. Costa DB, Shaw AT, Ou SH, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881-1888, 2015
10. Doebele RC, Lu X, Sumey C, et al: Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 118:4502-4511, 2012
11. Berger LA, Riesenberg H, Bokemeyer C, et al: CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives. Lung Cancer 80:242-248, 2013
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
13. Ou SH, Jänne PA, Bartlett CH, et al: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25:415-422, 2014
14. Rangachari D, Yamaguchi N, Vander Laan PA, et al: Brain metastases in patients with EGFRmutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88:108-111, 2015
15. Kinoshita Y, Koga Y, Sakamoto A, et al: Longlasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Rep 2013: pii: bcr-2013-200867, 2013
16. Kaneda H, Okamoto I, Nakagawa K: Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J Thorac Oncol 8:e32-e33, 2013
17. Metro G, Lunardi G, Floridi P, et al: CSF concentration of crizotinib in two ALK-positive non-smallcell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 10:e26-e27, 2015
18. Costa DB, Kobayashi S, Pandya SS, et al: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443-e445, 2011
19. Camidge DR: Taking aim at ALK across the blood-brain barrier. J Thorac Oncol 8:389-390, 2013
20. Takeda M, Okamoto I, Nakagawa K: Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8:654-657, 2013
21. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
22. Weickhardt AJ, Scheier B, Burke JM, et al: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7:1807-1814, 2012
23. Mok T, Spigel D, Felip E, et al: ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol 33:436s, 2015(suppl; abstr 8059)
24. Felip E, Orlov S, Park K, et al: ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol 33:436s, 2015(suppl; abstr 8060)
25. Ou SHI, Ahn JS, De Petris L, et al: Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-smallcell lung cancer (NSCLC) patientswho have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol 33:424s, 2015(suppl; abstr 8008)
26. Camidge DR, Bazhenova L, Salgia R, et al: Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small-cell lung cancer. J Clin Oncol 33:437s, 2015(suppl; abstr 8062)
27. Shaw AT, Bauer TM, Felip E, et al: Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol 33:426s, 2015(suppl; abstr 8018)